| Identification | Back Directory | [Name]
INF39 | [CAS]
866028-26-4 | [Synonyms]
INF39
CS-2508
INF39 >=98% (HPLC)
INF-39;INF 39;INF39
Ethyl 2-(2-chlorobenzyl)acrylate
Benzenepropanoic acid, 2-chloro-α-methylene-, ethyl ester | [Molecular Formula]
C12H13ClO2 | [MDL Number]
MFCD27930542 | [MOL File]
866028-26-4.mol | [Molecular Weight]
224.68 |
| Chemical Properties | Back Directory | [Boiling point ]
309.3±30.0 °C(Predicted) | [density ]
1.131±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO:66.0(Max Conc. mg/mL);293.75(Max Conc. mM)
Ethanol:30.0(Max Conc. mg/mL);133.52(Max Conc. mM) | [form ]
oil | [color ]
colorless to light brown | [InChI]
1S/C12H13ClO2/c1-3-15-12(14)9(2)8-10-6-4-5-7-11(10)13/h4-7H,2-3,8H2,1H3 | [InChIKey]
VTAOWWAFBSFWSG-UHFFFAOYSA-N | [SMILES]
ClC1=C(CC(C(OCC)=O)=C)C=CC=C1 |
| Hazard Information | Back Directory | [Uses]
INF 39 is a NLRP3 inflammasome inhibitor. Used in the treatment of inflammatory bowel disease. | [Biochem/physiol Actions]
INF39 is an orally active acrylate derivative and a non-cytotoxic INF4E analog (no toxicity at 100 μM in THP-1 cultures vs. TC50 = 65 μM with INF4E) that acts as an irreversible inhibitor against NLRP3 (NACHT, LRR and PYD domains-containing protein 3) ATPase activity (52% inhibition in 15 min by 100 μM INF39; 105 ng human NLP3 & 250 μM ATP) essential for the NLRP3 inflammasome assembly and activation. INF39 effectively decreases 5 mM (30 min) ATP-induced interleukin-1β (IL-1β) release and pyroptosis of murine bone marrow-derived macrophages in cultures (by 55-58% and 43-65%, respectively, with 1-hr 10 μM INF39 pretreatment of LPS-primed BMDM) and alleviates gut-associated inflammation in a rat model of 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis in vivo (12.5-50 mg/kg/day in 0.2 mL olive oil p.o.). | [in vivo]
Oral administration of INF39 reduces systemic and colonic inflammation in rats treated with 2,4- dinitrobenzenesulfonic acid. Significant increments of body weight are observed in inflamed rats under treatment with INF39 (12.5, 25, and 50 mg/ kg). Treatment with DNBS results in a significant increment of spleen weight (+39.3%). Such an increase is significantly reduced by administration of INF39 (+2.2, +4.3 and +4.8% at 12.5, 25, 50 mg/kg, respectively). The inhibition of NLRP3 inflammasome complex with INF39 dose-dependently attenuates the decrease in colonic length ( 19, 13 and 8% at 12.5, 25, 50 mg/kg, respectively). Rats treated with INF39 displays a significant reduction of macroscopic damage score (4.7 at 12.5 mg/kg, 3.1 at 25 mg/kg, and 2.8 at 50 mg/kg). Oral administration of INF39 reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats[1]. | [IC 50]
NLRP3 | [storage]
Store at -20°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|